It is likely that the proportion of enrolled patients with concurrent obesity and/or diabetes (ranged from 11% to 39%) who can have more pronounced activation of the NLRP3 inflammasome was too low to allow detection of mortality benefits (Table 1).21, 22. This evidence concerns the gene NLRP3 and Obesity.